NFE2L2 and hepatocellular carcinoma: NFE2L2 generally functions as a master negative regulator of ferroptosis, because activation of the SQSTM1–KEAP1–NFE2L2 pathway is an important homeostasis mechanism to block ferroptosis in hepatocellular carcinoma (HCC) induced by sorafenib.